

West Pharmaceutical Services, Inc.

First-Quarter 2017 Analyst Conference Call

9 a.m. Eastern Time, April 27, 2017

Speakers:

Eric M. Green
President and Chief Executive Officer

William J. Federici
Senior Vice President and Chief Financial Officer

- A webcast of today's call can be accessed in the "Investors" section of the Company's web site: www.westpharma.com
- To participate on the call please dial:
 - 877-930-8295 (U.S.)
 - 253-336-8738 (International).
 - The conference ID is 3829053
- An online archive of the broadcast will be available at the site three hours after the live call and will be available through Thursday, May 4, 2017, by dialing:
 - 855-859-2056 (U.S.)
 - 404-537-3406 (International)
 - The conference ID 3829053

These presentation materials are intended to accompany today's press release announcing the Company's results for the first-quarter 2017 and management's discussion of those results during today's conference call.



Safe Harbor Statement

Cautionary Statement Under the Private Securities Litigation Reform Act of 1995

This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product development and operational performance. Each of these statements is based on preliminary information, and actual results could differ from any preliminary estimates. We caution investors that the risk factors listed under “Cautionary Statement” in our press releases, as well as those set forth under the caption “Risk Factors” in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially from those estimated or predicted in the forward-looking statements. You should evaluate any statement in light of these important factors. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Non-U.S. GAAP Financial Measures

Certain financial measures included in these presentation materials, or which may be referred to in management’s discussion of the Company’s results and outlook, have not been calculated in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and therefore are referred to as non-GAAP financial measures. Non-GAAP financial measures should not be considered in isolation or as an alternative to such measures determined in accordance with GAAP. Please refer to “Reconciliation of Non-GAAP Measures” at the end of these materials for more information.

Trademarks

Registered trademarks used in this report are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless noted otherwise.

First-Quarter 2017 Highlights



- Net sales of \$387.7 million, representing 8.7% organic sales growth*
 - Proprietary Products organic sales growth of 8.0%
 - Contract-Manufactured Products organic sales growth of 11.4%
- Expanded gross profit margin by 60 basis points and adjusted operating profit margin by 40 basis points
- Launched new high-value products including LyoSeal[®] cap, an all-plastic, instant sealing solution for lyophilized drug products, and NovaGuard[®] SA Pro, a safety system to aid in the protection against accidental needlesticks
- Commenced commercial production at expanded Dublin contract manufacturing site. Remain on schedule for first phase at Waterford, Ireland facility.
- Record-high reported diluted EPS of \$0.81, a 52% increase over prior-year adjusted diluted EPS
 - Excluding tax benefits from stock-based compensation expenses, adjusted diluted EPS would have grown by 13% over prior-year quarter

* Excluding the impact from translational changes in foreign exchange


Organic Sales Growth



	Q1 2016	Q2 2016	Q3 2016	Q4 2016	Q1 2017	FY 2017E
Overall Organic Sales Growth	10.5%	8.2%	10.0%	7.7%	8.7%	7-9%
Pharma	MSD	HSD	MSD	HSD	DD	HSD
Generics	DD	DD	HSD	(MSD)	(MSD)	MSD
Biologics	DD	HSD	DD	DD	MSD	DD
Contract Manufacturing	LSD	MSD	MSD	DD	DD	HSD

Abbreviations: LSD – low-single digit; MSD – mid-single digit; HSD – high-single digit; DD – double digit

Our Pipeline of New Products is Robust



2017 Outlook

- Maintaining full-year 2017 net sales organic sales growth guidance in a range of 7% to 9%
- 2017 net sales range: \$1.585 billion to \$1.610 billion
- Raising 2017 reported diluted EPS guidance to a new range of \$2.66 to \$2.78 compared to a prior range of \$2.45 to \$2.57



First Quarter 2017 Summary Results


(\$ millions, except earnings-per-share (EPS) data)

	Three Months Ended	
	March 31,	
	2017	2016
Reported Net Sales	\$387.7	\$362.1
Net Sales at Constant Currency⁽¹⁾	\$393.5	\$362.1
Gross Profit Margin	34.6 %	34.0 %
Reported Operating Profit	\$61.3	\$30.0
Adjusted Operating Profit⁽¹⁾	\$61.3	\$55.6
Diluted EPS	\$0.81	\$0.30
Adjusted Diluted EPS⁽¹⁾	\$0.81	\$0.53

(1) “Net sales at constant currency”, “adjusted operating profit”, and “adjusted diluted EPS” are Non-GAAP measures. See slides 13-16 and the discussion under the heading “Non-GAAP Financial Measures” in today’s press release for an explanation and reconciliation of these items. Except as noted, statements in these slides concerning comparative sales are measured on a constant currency basis.

Change in Consolidated Sales


First quarter 2016 to 2017
(\$ millions)



* Includes \$4.9 million of inflationary increases in South America.


Change in Gross Profit Margin %

First quarter 2016 to 2017



Change in SG&A Costs

First quarter 2016 to 2017
(\$ millions)



Cash Flow and Balance Sheet Metrics

(\$ millions)

CASH FLOW ITEMS

(UNAUDITED)
(in millions)

	Three Months Ended March 31,	
	2017	2016
Depreciation and amortization	\$23.3	\$22.3
Operating cash flow ⁽¹⁾	\$20.7	\$3.0
Capital expenditures	\$37.5	\$39.0

⁽¹⁾ 2017 includes a tax benefit of \$15.9 million associated with the adoption of guidance issued by the Financial Accounting Standards Board regarding share-based payment transactions.

FINANCIAL CONDITION

(UNAUDITED)
(in millions)

	As of March 31, 2017	As of December 31, 2016
Cash and cash equivalents	\$169.4	\$203.0
Debt	\$228.6	\$228.6
Equity	\$1,168.6	\$1,117.5
Net debt-to-total invested capital	4.8%	2.2%
Working capital	\$396.1	\$400.9

2017 Full-Year Guidance

(\$ millions, except EPS) (1) (2) (3)

	2017 Updated Guidance	Prior Guidance
Proprietary Products net sales	no change	\$1,245 to \$1,260
Contract-Manufactured Products net sales	no change	\$340 to \$350
Consolidated net sales	no change	\$1,585 to \$1,610
Consolidated gross profit margin (% of net sales)	no change	34.4% to 34.8%
Full-year reported diluted EPS (1) (2) (3)	\$2.66 to \$2.78	\$2.45 to \$2.57

⁽¹⁾ Guidance includes various currency exchange rate assumptions, most significantly the euro at \$1.05 for 2017. Actual results will vary as a result of variability of exchange rates, among other items.

⁽²⁾ We continue to actively monitor the political and economic developments in Venezuela, particularly as we have recently experienced reduced access to USD controlled by their government. If there are further devaluations or other changes, a pre-tax charge of up to \$15 million could be required. Our reported diluted EPS guidance excludes the potential impact of a Venezuela deconsolidation.

⁽³⁾ Includes previously-discussed tax benefit of \$15.9 million (\$0.21 per diluted share).

Notes to Non-GAAP Financial Measures

For additional details, please see today's press release & Safe Harbor Statement

Today's press release, these presentation materials and associated presentation use the following financial measures that have not been calculated in accordance with generally accepted accounting principles (GAAP) accepted in the U.S., and therefore are referred to as non-GAAP financial measures:

- Net sales at constant currency (organic sales)
- Adjusted operating profit
- Adjusted operating profit margin
- Adjusted net income
- Adjusted income tax expense
- Adjusted diluted EPS
- Net debt
- Total invested capital
- Net debt to total invested capital

West believes that these non-GAAP measures of financial results provide useful information to management and investors regarding business trends, results of operations, and the Company's overall performance and financial position. Our executive management team uses these financial measures to evaluate the performance of the Company in terms of profitability and efficiency, to compare operating results to prior periods, to evaluate changes in the operating results of each segment, and to measure and allocate financial resources to our segments. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in comparing its financial measures with other companies.

Our executive management does not consider such non-GAAP measures in isolation or as an alternative to such measures determined in accordance with GAAP. The principal limitation of these financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. In order to compensate for these limitations, non-GAAP financial measures are presented in connection with GAAP results. We urge investors and potential investors to review the reconciliations of our non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate the Company's business.

Net sales at constant currency translates the current-period reported sales of subsidiaries whose functional currency is other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period. In calculating adjusted operating profit, adjusted income tax expense, adjusted net income and adjusted diluted EPS, we exclude the impact of items that are not considered representative of ongoing operations. Such items generally include restructuring and related costs, certain asset impairments, other specifically identified gains or losses, and discrete income tax items.

Please see "Financial Guidance" and "Non-GAAP Financial Measures" in today's press release for further information concerning reconciling items.

Notes to Non-GAAP Financial Measures

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

See “Notes to Non-GAAP Financial Measures” (Slide 13-16), “Cautionary Statement” (Slide 2) and today’s press release for an explanation and reconciliation of these items.

Reconciliation of Reported and Adjusted Operating Profit, Net Income and Diluted EPS (\$ million, except EPS data)

Three months ended March 31, 2016	Operating profit	Income tax expense	Net income	Diluted EPS
Reported (GAAP)	\$30.0	\$6.9	\$22.1	\$0.30
Restructuring and related charges	22.9	7.9	15.0	0.20
Venezuela currency devaluation	2.7	0.2	2.5	0.03
Adjusted (Non-GAAP)	\$55.6	\$15.0	\$39.6	\$0.53

Notes to Non-GAAP Financial Measures

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

See “Notes to Non-GAAP Financial Measures” (Slide 13-16), “Cautionary Statement” (Slide 2) and today’s press release for an explanation and reconciliation of these items.

Reconciliation of Net Sales to Net Sales at Constant Currency⁽¹⁾ (\$ million, except EPS data)

Three months ended March 31, 2017	Proprietary	CM	Eliminations	Total
Reported net sales (GAAP)	\$308.8	\$79.1	\$(0.2)	\$387.7
Effect of changes in currency translation rates	5.2	0.6	-	5.8
Net sales at constant currency (Non-GAAP) ⁽¹⁾	\$314.0	\$79.7	\$(0.2)	\$393.5

⁽¹⁾ Net sales at constant currency translates the current-period reported sales of subsidiaries whose functional currency is other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period.

Notes to Non-GAAP Financial Measures

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)

See “Notes to Non-GAAP Financial Measures” (Slide 13-16), “Cautionary Statement” (Slide 2) and today’s press release for an explanation and reconciliation of these items.

	Full Year 2017 Guidance ^{(1) (2) (3)}
Reported diluted EPS guidance	\$2.66 to \$2.78

⁽¹⁾ Guidance includes various currency exchange rate assumptions, most significantly the euro at \$1.05 for the remainder of 2017. Actual results will vary as a result of exchange rate variability.

⁽²⁾ Includes previously-discussed tax benefit of \$15.9 million (\$0.21 per diluted share).

⁽³⁾ We continue to actively monitor the political and economic developments in Venezuela, particularly as we have recently experienced reduced access to USD controlled by their government. If there are further devaluations or other changes, a pre-tax charge of up to \$15 million could be required. Our reported diluted EPS guidance excludes the potential impact of the Venezuela deconsolidation.